First Financial Bank N.A. Trust Division raised its position in shares of Eli Lilly and Co. (NYSE:LLY) by 2.3% during the third quarter, according to its most recent 13F filing with the SEC. The fund owned 16,105 shares of the company’s stock after buying an additional 360 shares during the period. First Financial Bank N.A. Trust Division’s holdings in Eli Lilly and were worth $1,292,000 at the end of the most recent quarter.
Several other large investors have also bought and sold shares of the stock. Iowa State Bank acquired a new stake in Eli Lilly and during the second quarter worth approximately $104,000. PineBridge Investments L.P. boosted its stake in Eli Lilly and by 208.6% in the second quarter. PineBridge Investments L.P. now owns 1,361 shares of the company’s stock worth $108,000 after buying an additional 920 shares during the period. Cribstone Capital Management LLC acquired a new stake in Eli Lilly and during the second quarter worth approximately $117,000. Coconut Grove Bank boosted its stake in Eli Lilly and by 3.3% in the second quarter. Coconut Grove Bank now owns 1,550 shares of the company’s stock worth $122,000 after buying an additional 50 shares during the period. Finally, Physicians Financial Services Inc. boosted its stake in Eli Lilly and by 11.2% in the second quarter. Physicians Financial Services Inc. now owns 1,638 shares of the company’s stock worth $129,000 after buying an additional 165 shares during the period. Hedge funds and other institutional investors own 75.11% of the company’s stock.
Eli Lilly and Co. (NYSE:LLY) traded up 1.65% during trading on Friday, hitting $69.12. 8,620,682 shares of the company’s stock traded hands. The firm’s 50-day moving average price is $76.69 and its 200 day moving average price is $77.92. Eli Lilly and Co. has a 12-month low of $64.18 and a 12-month high of $88.16. The stock has a market cap of $73.11 billion, a P/E ratio of 30.07 and a beta of 0.28.
Eli Lilly and (NYSE:LLY) last released its quarterly earnings results on Tuesday, October 25th. The company reported $0.88 EPS for the quarter, missing the consensus estimate of $0.96 by $0.08. The business earned $5.19 billion during the quarter, compared to analyst estimates of $4.23 billion. Eli Lilly and had a net margin of 11.73% and a return on equity of 23.71%. The firm’s revenue for the quarter was up 4.7% compared to the same quarter last year. During the same quarter in the prior year, the company earned $0.89 earnings per share. Analysts anticipate that Eli Lilly and Co. will post $3.55 earnings per share for the current fiscal year.
The firm also recently declared a quarterly dividend, which will be paid on Friday, December 9th. Stockholders of record on Tuesday, November 15th will be given a $0.51 dividend. The ex-dividend date is Thursday, November 10th. This represents a $2.04 annualized dividend and a dividend yield of 2.95%. Eli Lilly and’s dividend payout ratio is presently 88.70%.
Several equities research analysts recently issued reports on the company. Leerink Swann reiterated an “outperform” rating and issued a $105.00 price objective on shares of Eli Lilly and in a report on Saturday, August 13th. Citigroup Inc. reiterated a “buy” rating on shares of Eli Lilly and in a report on Tuesday, November 8th. Zacks Investment Research upgraded Eli Lilly and from a “hold” rating to a “buy” rating and set a $88.00 price objective on the stock in a report on Thursday, October 20th. JPMorgan Chase & Co. set a $85.00 price objective on Eli Lilly and and gave the stock a “buy” rating in a report on Thursday. Finally, BMO Capital Markets reiterated an “outperform” rating and issued a $94.00 price objective on shares of Eli Lilly and in a report on Tuesday, September 27th. Four analysts have rated the stock with a hold rating and seventeen have given a buy rating to the company. Eli Lilly and currently has a consensus rating of “Buy” and an average price target of $108.34.
In other news, insider Maria A. Crowe sold 2,248 shares of the stock in a transaction that occurred on Wednesday, October 5th. The shares were sold at an average price of $81.37, for a total value of $182,919.76. Following the sale, the insider now directly owns 94,319 shares in the company, valued at $7,674,737.03. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.20% of the stock is currently owned by insiders.
About Eli Lilly and
Eli Lilly and Company is engaged in drug manufacturing business. The Company discovers, develops, manufactures and markets products in two segments: human pharmaceutical products and animal health products. The Company’s human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists.